Our technologies

We are developing platforms to screen the medicines of tomorrow for side effects and provide patients with safer and better treatments.

Image - Our Technologies

Overview

ABS Biotechnologies provides ready-made and custom hiPSC solutions (workhorse hiPSC lines and custom reprogramming service) alongside advanced cardiovascular cell models that enable more human-relevant disease research and safer drug development.

Workhorse hiPSCs

human induced Pluripotent Stem Cells

Ready-to-order, research-grade hiPSC lines that are quality-controlled, genetically stable, and available off the shelf. These cells provide a reliable starting material for disease modelling, drug discovery, and differentiation into specialised cell types. ABS Biotechnologies values high quality, reproducibility, and ethnic diversity via its portfolio.

Learn more about Workhorse hiPSCs »

Custom hiPSC reprogramming

A service for reprogramming of customers' samples (whole blood or skin biopsies) into custom hiPSC lines. ABS Biotechnologies handles the reprogramming process, quality control, genetic validation, and pluripotency testing, delivering bespoke stem cell lines tailored to specific research or development projects. Typical turnaround is four months.

Learn more about Custom hiPSC reprogramming »

SMC

Smooth Muscle Cells

Human vascular smooth muscle cells derived from hiPSCs and engineered to represent different regions of the vascular system. These cells are designed for cardiovascular research and drug toxicity testing, helping researchers identify vascular side effects such as those linked to hypertension, stroke, or heart attack risk that may not be detected in conventional models.

Learn more about SMC »

EPI

Epicardium-derived Cardiomyocyte Maturation Booster

Used to improve the maturation and functionality of stem-cell-derived heart tissue. ABS Biotechnologies' proprietary epicardial technology enhances the development of more physiologically relevant cardiomyocytes, enabling more accurate prediction of cardiac drug responses and arrhythmia risks during preclinical testing.

Learn more about EPI »